Comparison of Ivermectin and Diethylcarbamazine in the Treatment of Onchocerciasis
We compared ivermectin with diethylcarbamazine for the treatment of onchocerciasis in a double-blind, placebo-controlled trial. Thirty men with moderate to heavy infection and ocular involvement were randomly assigned to receive ivermectin in a single oral dose (200 μg per kilogram of body weight),...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1985-07, Vol.313 (3), p.133-138 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 138 |
|---|---|
| container_issue | 3 |
| container_start_page | 133 |
| container_title | The New England journal of medicine |
| container_volume | 313 |
| creator | Greene, Bruce M Taylor, Hugh R Cupp, Eddie W Murphy, Robert P White, Albert T Aziz, Mohammed A Schulz-Key, Hartwig D'Anna, Salvatore A Newland, Henry S Goldschmidt, Leonard P Auer, Cheryl Hanson, Aloysius P Freeman, S. Vaanii Reber, Earl W Williams, P. Noel |
| description | We compared ivermectin with diethylcarbamazine for the treatment of onchocerciasis in a double-blind, placebo-controlled trial. Thirty men with moderate to heavy infection and ocular involvement were randomly assigned to receive ivermectin in a single oral dose (200 μg per kilogram of body weight), diethylcarbamazine daily for eight days, or placebo. Diethylcarbamazine caused a significantly more severe systemic reaction than ivermectin (P |
| doi_str_mv | 10.1056/NEJM198507183130301 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1878185052</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4320927005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-7e8d928244018327191da7feca784ea390f907d460917711b2f3dba0a91f56332</originalsourceid><addsrcrecordid>eNp9kEFLAzEQhYMotVZ_gQgLepPVTLLbJEepVSvVgtTzMs1m6ZYmW5OtUH-9KS09iXOZw_vezOMRcgn0Dmjev38fvr6BkjkVIDlwyikckS7knKdZRvvHpEspk2kmFD8lZyEsaBzIVId0uFSMKd4lH4PGrtDXoXFJUyWjb-Ot0W3tEnRl8libdr5ZavQztPhTO5NEpZ2bZOoNtta4duuaOD1vtPG6xlCHc3JS4TKYi_3ukc-n4XTwko4nz6PBwzjVGadtKowsFZMsRo3xmQAFJYrKaBQyM8gVrRQVZdanCoQAmLGKlzOkqKDK-5yzHrne3V355mttQlssmrV38WUBUkiIxeQsUnxHad-E4E1VrHxt0W8KoMW2xuKPGqPran97PbOmPHj2vUX9Zq9j0LisPDpdhwOmWA4ykxG73WHWhsKZhf336S_IFYTD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1878185052</pqid></control><display><type>article</type><title>Comparison of Ivermectin and Diethylcarbamazine in the Treatment of Onchocerciasis</title><source>MEDLINE</source><creator>Greene, Bruce M ; Taylor, Hugh R ; Cupp, Eddie W ; Murphy, Robert P ; White, Albert T ; Aziz, Mohammed A ; Schulz-Key, Hartwig ; D'Anna, Salvatore A ; Newland, Henry S ; Goldschmidt, Leonard P ; Auer, Cheryl ; Hanson, Aloysius P ; Freeman, S. Vaanii ; Reber, Earl W ; Williams, P. Noel</creator><creatorcontrib>Greene, Bruce M ; Taylor, Hugh R ; Cupp, Eddie W ; Murphy, Robert P ; White, Albert T ; Aziz, Mohammed A ; Schulz-Key, Hartwig ; D'Anna, Salvatore A ; Newland, Henry S ; Goldschmidt, Leonard P ; Auer, Cheryl ; Hanson, Aloysius P ; Freeman, S. Vaanii ; Reber, Earl W ; Williams, P. Noel</creatorcontrib><description>We compared ivermectin with diethylcarbamazine for the treatment of onchocerciasis in a double-blind, placebo-controlled trial. Thirty men with moderate to heavy infection and ocular involvement were randomly assigned to receive ivermectin in a single oral dose (200 μg per kilogram of body weight), diethylcarbamazine daily for eight days, or placebo. Diethylcarbamazine caused a significantly more severe systemic reaction than ivermectin (P<0.001), whereas the reaction to ivermectin did not differ from the reaction to placebo. Diethylcarbamazine markedly increased the number of punctate opacities in the eye (P<0.001), as well as the number of dead and living microfilariae in the cornea over the first week of therapy. Ivermectin had no such effect. Both ivermectin and diethylcarbamazine promptly reduced skin microfilaria counts, but only in the ivermectin group did counts remain significantly lower (P<0.005) than in the placebo group at the end of six months of observation. Analysis of adult worms isolated from nodules obtained two months after the start of therapy showed no effect of either drug on viability. Ivermectin appears to be a better tolerated, safer, and more effective microfilaricidal agent than diethylcarbamazine for the treatment of onchocerciasis. (N Engl J Med 1985; 313:133–8.)
TREATMENT of
Onchocerca volvulus
infection, a major filarial disease among human beings and one of the leading causes of blindness, remains problematic. Diethylcarbamazine, the most widely used agent, has frequent side effects and complications.
1
2
3
4
5
6
These include a variety of symptomatic effects, such as pruritus, lymph-node pain, myalgias and arthralgias, headache, dizziness, and conjunctivitis, as well as more serious complications, such as hypotension, keratitis, chorioretinal damage, and optic neuritis. It is therefore recommended that diethylcarbamazine be used conservatively and only for clear indications, such as sight-threatening or debilitating disease.
7
,
8
Suramin, the other available drug, is impractical for mass therapy since it . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM198507183130301</identifier><identifier>PMID: 3892293</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Adult ; Anthelmintics - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiparasitic Agents ; Biological and medical sciences ; Biomedical research ; Body weight ; Clinical Trials as Topic ; Cornea ; Cornea - parasitology ; Corneal Opacity - chemically induced ; Diethylcarbamazine - adverse effects ; Diethylcarbamazine - therapeutic use ; Dirofilaria immitis ; Double-Blind Method ; Eye Diseases - drug therapy ; Eye Diseases - etiology ; Filaricides - adverse effects ; Filaricides - therapeutic use ; Hospitals ; Humans ; Infections ; Ivermectin ; Laboratories ; Lactones - adverse effects ; Lactones - therapeutic use ; Male ; Medical imaging ; Medical sciences ; Medicine ; Middle Aged ; Nodules ; Onchocerca volvulus ; Onchocerciasis ; Onchocerciasis - complications ; Onchocerciasis - drug therapy ; Onchocerciasis - parasitology ; Pharmacology. Drug treatments ; Pruritus ; Random Allocation ; Skin ; Skin - parasitology ; Skin Diseases, Parasitic - parasitology ; Time Factors</subject><ispartof>The New England journal of medicine, 1985-07, Vol.313 (3), p.133-138</ispartof><rights>1985 INIST-CNRS</rights><rights>Copyright Massachusetts Medical Society Jul 18, 1985</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-7e8d928244018327191da7feca784ea390f907d460917711b2f3dba0a91f56332</citedby><cites>FETCH-LOGICAL-c430t-7e8d928244018327191da7feca784ea390f907d460917711b2f3dba0a91f56332</cites></display><links><openurl>$$Topenurl_article</openurl><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9251848$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3892293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Greene, Bruce M</creatorcontrib><creatorcontrib>Taylor, Hugh R</creatorcontrib><creatorcontrib>Cupp, Eddie W</creatorcontrib><creatorcontrib>Murphy, Robert P</creatorcontrib><creatorcontrib>White, Albert T</creatorcontrib><creatorcontrib>Aziz, Mohammed A</creatorcontrib><creatorcontrib>Schulz-Key, Hartwig</creatorcontrib><creatorcontrib>D'Anna, Salvatore A</creatorcontrib><creatorcontrib>Newland, Henry S</creatorcontrib><creatorcontrib>Goldschmidt, Leonard P</creatorcontrib><creatorcontrib>Auer, Cheryl</creatorcontrib><creatorcontrib>Hanson, Aloysius P</creatorcontrib><creatorcontrib>Freeman, S. Vaanii</creatorcontrib><creatorcontrib>Reber, Earl W</creatorcontrib><creatorcontrib>Williams, P. Noel</creatorcontrib><title>Comparison of Ivermectin and Diethylcarbamazine in the Treatment of Onchocerciasis</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>We compared ivermectin with diethylcarbamazine for the treatment of onchocerciasis in a double-blind, placebo-controlled trial. Thirty men with moderate to heavy infection and ocular involvement were randomly assigned to receive ivermectin in a single oral dose (200 μg per kilogram of body weight), diethylcarbamazine daily for eight days, or placebo. Diethylcarbamazine caused a significantly more severe systemic reaction than ivermectin (P<0.001), whereas the reaction to ivermectin did not differ from the reaction to placebo. Diethylcarbamazine markedly increased the number of punctate opacities in the eye (P<0.001), as well as the number of dead and living microfilariae in the cornea over the first week of therapy. Ivermectin had no such effect. Both ivermectin and diethylcarbamazine promptly reduced skin microfilaria counts, but only in the ivermectin group did counts remain significantly lower (P<0.005) than in the placebo group at the end of six months of observation. Analysis of adult worms isolated from nodules obtained two months after the start of therapy showed no effect of either drug on viability. Ivermectin appears to be a better tolerated, safer, and more effective microfilaricidal agent than diethylcarbamazine for the treatment of onchocerciasis. (N Engl J Med 1985; 313:133–8.)
TREATMENT of
Onchocerca volvulus
infection, a major filarial disease among human beings and one of the leading causes of blindness, remains problematic. Diethylcarbamazine, the most widely used agent, has frequent side effects and complications.
1
2
3
4
5
6
These include a variety of symptomatic effects, such as pruritus, lymph-node pain, myalgias and arthralgias, headache, dizziness, and conjunctivitis, as well as more serious complications, such as hypotension, keratitis, chorioretinal damage, and optic neuritis. It is therefore recommended that diethylcarbamazine be used conservatively and only for clear indications, such as sight-threatening or debilitating disease.
7
,
8
Suramin, the other available drug, is impractical for mass therapy since it . . .</description><subject>Adult</subject><subject>Anthelmintics - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiparasitic Agents</subject><subject>Biological and medical sciences</subject><subject>Biomedical research</subject><subject>Body weight</subject><subject>Clinical Trials as Topic</subject><subject>Cornea</subject><subject>Cornea - parasitology</subject><subject>Corneal Opacity - chemically induced</subject><subject>Diethylcarbamazine - adverse effects</subject><subject>Diethylcarbamazine - therapeutic use</subject><subject>Dirofilaria immitis</subject><subject>Double-Blind Method</subject><subject>Eye Diseases - drug therapy</subject><subject>Eye Diseases - etiology</subject><subject>Filaricides - adverse effects</subject><subject>Filaricides - therapeutic use</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infections</subject><subject>Ivermectin</subject><subject>Laboratories</subject><subject>Lactones - adverse effects</subject><subject>Lactones - therapeutic use</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Middle Aged</subject><subject>Nodules</subject><subject>Onchocerca volvulus</subject><subject>Onchocerciasis</subject><subject>Onchocerciasis - complications</subject><subject>Onchocerciasis - drug therapy</subject><subject>Onchocerciasis - parasitology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pruritus</subject><subject>Random Allocation</subject><subject>Skin</subject><subject>Skin - parasitology</subject><subject>Skin Diseases, Parasitic - parasitology</subject><subject>Time Factors</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>false</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kEFLAzEQhYMotVZ_gQgLepPVTLLbJEepVSvVgtTzMs1m6ZYmW5OtUH-9KS09iXOZw_vezOMRcgn0Dmjev38fvr6BkjkVIDlwyikckS7knKdZRvvHpEspk2kmFD8lZyEsaBzIVId0uFSMKd4lH4PGrtDXoXFJUyWjb-Ot0W3tEnRl8libdr5ZavQztPhTO5NEpZ2bZOoNtta4duuaOD1vtPG6xlCHc3JS4TKYi_3ukc-n4XTwko4nz6PBwzjVGadtKowsFZMsRo3xmQAFJYrKaBQyM8gVrRQVZdanCoQAmLGKlzOkqKDK-5yzHrne3V355mttQlssmrV38WUBUkiIxeQsUnxHad-E4E1VrHxt0W8KoMW2xuKPGqPran97PbOmPHj2vUX9Zq9j0LisPDpdhwOmWA4ykxG73WHWhsKZhf336S_IFYTD</recordid><startdate>19850718</startdate><enddate>19850718</enddate><creator>Greene, Bruce M</creator><creator>Taylor, Hugh R</creator><creator>Cupp, Eddie W</creator><creator>Murphy, Robert P</creator><creator>White, Albert T</creator><creator>Aziz, Mohammed A</creator><creator>Schulz-Key, Hartwig</creator><creator>D'Anna, Salvatore A</creator><creator>Newland, Henry S</creator><creator>Goldschmidt, Leonard P</creator><creator>Auer, Cheryl</creator><creator>Hanson, Aloysius P</creator><creator>Freeman, S. Vaanii</creator><creator>Reber, Earl W</creator><creator>Williams, P. Noel</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>19850718</creationdate><title>Comparison of Ivermectin and Diethylcarbamazine in the Treatment of Onchocerciasis</title><author>Greene, Bruce M ; Taylor, Hugh R ; Cupp, Eddie W ; Murphy, Robert P ; White, Albert T ; Aziz, Mohammed A ; Schulz-Key, Hartwig ; D'Anna, Salvatore A ; Newland, Henry S ; Goldschmidt, Leonard P ; Auer, Cheryl ; Hanson, Aloysius P ; Freeman, S. Vaanii ; Reber, Earl W ; Williams, P. Noel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-7e8d928244018327191da7feca784ea390f907d460917711b2f3dba0a91f56332</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Adult</topic><topic>Anthelmintics - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiparasitic Agents</topic><topic>Biological and medical sciences</topic><topic>Biomedical research</topic><topic>Body weight</topic><topic>Clinical Trials as Topic</topic><topic>Cornea</topic><topic>Cornea - parasitology</topic><topic>Corneal Opacity - chemically induced</topic><topic>Diethylcarbamazine - adverse effects</topic><topic>Diethylcarbamazine - therapeutic use</topic><topic>Dirofilaria immitis</topic><topic>Double-Blind Method</topic><topic>Eye Diseases - drug therapy</topic><topic>Eye Diseases - etiology</topic><topic>Filaricides - adverse effects</topic><topic>Filaricides - therapeutic use</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infections</topic><topic>Ivermectin</topic><topic>Laboratories</topic><topic>Lactones - adverse effects</topic><topic>Lactones - therapeutic use</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Middle Aged</topic><topic>Nodules</topic><topic>Onchocerca volvulus</topic><topic>Onchocerciasis</topic><topic>Onchocerciasis - complications</topic><topic>Onchocerciasis - drug therapy</topic><topic>Onchocerciasis - parasitology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pruritus</topic><topic>Random Allocation</topic><topic>Skin</topic><topic>Skin - parasitology</topic><topic>Skin Diseases, Parasitic - parasitology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><creatorcontrib>Greene, Bruce M</creatorcontrib><creatorcontrib>Taylor, Hugh R</creatorcontrib><creatorcontrib>Cupp, Eddie W</creatorcontrib><creatorcontrib>Murphy, Robert P</creatorcontrib><creatorcontrib>White, Albert T</creatorcontrib><creatorcontrib>Aziz, Mohammed A</creatorcontrib><creatorcontrib>Schulz-Key, Hartwig</creatorcontrib><creatorcontrib>D'Anna, Salvatore A</creatorcontrib><creatorcontrib>Newland, Henry S</creatorcontrib><creatorcontrib>Goldschmidt, Leonard P</creatorcontrib><creatorcontrib>Auer, Cheryl</creatorcontrib><creatorcontrib>Hanson, Aloysius P</creatorcontrib><creatorcontrib>Freeman, S. Vaanii</creatorcontrib><creatorcontrib>Reber, Earl W</creatorcontrib><creatorcontrib>Williams, P. Noel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>no_fulltext</fulltext></delivery><addata><au>Greene, Bruce M</au><au>Taylor, Hugh R</au><au>Cupp, Eddie W</au><au>Murphy, Robert P</au><au>White, Albert T</au><au>Aziz, Mohammed A</au><au>Schulz-Key, Hartwig</au><au>D'Anna, Salvatore A</au><au>Newland, Henry S</au><au>Goldschmidt, Leonard P</au><au>Auer, Cheryl</au><au>Hanson, Aloysius P</au><au>Freeman, S. Vaanii</au><au>Reber, Earl W</au><au>Williams, P. Noel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Ivermectin and Diethylcarbamazine in the Treatment of Onchocerciasis</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1985-07-18</date><risdate>1985</risdate><volume>313</volume><issue>3</issue><spage>133</spage><epage>138</epage><pages>133-138</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>We compared ivermectin with diethylcarbamazine for the treatment of onchocerciasis in a double-blind, placebo-controlled trial. Thirty men with moderate to heavy infection and ocular involvement were randomly assigned to receive ivermectin in a single oral dose (200 μg per kilogram of body weight), diethylcarbamazine daily for eight days, or placebo. Diethylcarbamazine caused a significantly more severe systemic reaction than ivermectin (P<0.001), whereas the reaction to ivermectin did not differ from the reaction to placebo. Diethylcarbamazine markedly increased the number of punctate opacities in the eye (P<0.001), as well as the number of dead and living microfilariae in the cornea over the first week of therapy. Ivermectin had no such effect. Both ivermectin and diethylcarbamazine promptly reduced skin microfilaria counts, but only in the ivermectin group did counts remain significantly lower (P<0.005) than in the placebo group at the end of six months of observation. Analysis of adult worms isolated from nodules obtained two months after the start of therapy showed no effect of either drug on viability. Ivermectin appears to be a better tolerated, safer, and more effective microfilaricidal agent than diethylcarbamazine for the treatment of onchocerciasis. (N Engl J Med 1985; 313:133–8.)
TREATMENT of
Onchocerca volvulus
infection, a major filarial disease among human beings and one of the leading causes of blindness, remains problematic. Diethylcarbamazine, the most widely used agent, has frequent side effects and complications.
1
2
3
4
5
6
These include a variety of symptomatic effects, such as pruritus, lymph-node pain, myalgias and arthralgias, headache, dizziness, and conjunctivitis, as well as more serious complications, such as hypotension, keratitis, chorioretinal damage, and optic neuritis. It is therefore recommended that diethylcarbamazine be used conservatively and only for clear indications, such as sight-threatening or debilitating disease.
7
,
8
Suramin, the other available drug, is impractical for mass therapy since it . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>3892293</pmid><doi>10.1056/NEJM198507183130301</doi><tpages>6</tpages></addata></record> |
| fulltext | no_fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1985-07, Vol.313 (3), p.133-138 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_1878185052 |
| source | MEDLINE |
| subjects | Adult Anthelmintics - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiparasitic Agents Biological and medical sciences Biomedical research Body weight Clinical Trials as Topic Cornea Cornea - parasitology Corneal Opacity - chemically induced Diethylcarbamazine - adverse effects Diethylcarbamazine - therapeutic use Dirofilaria immitis Double-Blind Method Eye Diseases - drug therapy Eye Diseases - etiology Filaricides - adverse effects Filaricides - therapeutic use Hospitals Humans Infections Ivermectin Laboratories Lactones - adverse effects Lactones - therapeutic use Male Medical imaging Medical sciences Medicine Middle Aged Nodules Onchocerca volvulus Onchocerciasis Onchocerciasis - complications Onchocerciasis - drug therapy Onchocerciasis - parasitology Pharmacology. Drug treatments Pruritus Random Allocation Skin Skin - parasitology Skin Diseases, Parasitic - parasitology Time Factors |
| title | Comparison of Ivermectin and Diethylcarbamazine in the Treatment of Onchocerciasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A50%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Ivermectin%20and%20Diethylcarbamazine%20in%20the%20Treatment%20of%20Onchocerciasis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Greene,%20Bruce%20M&rft.date=1985-07-18&rft.volume=313&rft.issue=3&rft.spage=133&rft.epage=138&rft.pages=133-138&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM198507183130301&rft_dat=%3Cproquest_cross%3E4320927005%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1878185052&rft_id=info:pmid/3892293&rfr_iscdi=true |